$10,000 on new drugs every four months keeps melanoma patient alive

21 October 2020 - Graham Venning was given “weeks perhaps months” to live at the start of the year but ...

Read more →

Priority review granted to Ascentage Pharma's new drug application for olverembatinib (HQP1351), the first third generation BCR-ABL inhibitor in China

21 October 2020 - Ascentage Pharma today announced that the Center for Drug Evaluation of China's National Medical Products Administration has ...

Read more →

NICE recommended use of Opdivo for another indication

20 October 2020 - This marks the tenth NICE recommendation for nivolumab. ...

Read more →

TG Therapeutics announces fast track designation granted by the FDA to ublituximab in combination with umbralisib for the treatment of adult patients with chronic lymphocytic leukaemia

21 October 2020 - TG Therapeutics today announced that the U.S. FDA has granted fast track designation to the combination of ...

Read more →

‘It really seems cruel’: drug giant’s brutal blow to Australian breast cancer patients

21 October 2020 - Terminally ill breast cancer patients will have to pay $1,600 a month for a lifesaving treatment, after ...

Read more →

Tagrisso granted priority review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

20 October 2020 - Unprecedented results show treatment with Tagrisso reduced the risk of disease recurrence or death by 80% in ...

Read more →

U.S. Food and Drug Administration accepts for priority review applications for Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) in advanced renal cell carcinoma

19 October 2020 - U.S. Food and Drug Administration assigned a target action date of 20 February 2021. ...

Read more →

Bristol Myers Squibb receives positive CHMP opinion recommending Opdivo (nivolumab) as second-line treatment for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma

16 October 2020 - Application based on Phase 3 ATTRACTION-3 trial demonstrating a statistically significant and clinically meaningful improvement in patients’ ...

Read more →

First CAR-T cell medicine for mantle cell lymphoma

16 October 2020 - EMA has recommended granting a conditional marketing authorisation in the European Union for Tecartus (autologous anti-CD19 ...

Read more →

Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma

15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial. ...

Read more →

Venclexta (venetoclax) receives FDA full approval for acute myeloid leukaemia

16 October 2020 - The FDA approval of Venclexta for newly diagnosed AML patients who are ineligible for intensive chemotherapy is ...

Read more →

EMA cancer symposium: new approaches in patient-focused cancer medicine development

15 October 2020 - On Thursday, 29 October, EMA is hosting a symposium to discuss new approaches to facilitating and ...

Read more →

FDA approves expanded indication for Merck’s Keytruda (pembrolizumab) in adult patients with relapsed or refractory classical Hodgkin lymphoma

15 October 2020 - Keytruda is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory classic Hodgkin lymphoma ...

Read more →

Scotland backs two myeloma drugs turned down by NICE in England

14 October 2020 - A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines ...

Read more →

CTI BioPharma initiates rolling submission of new drug application for pacritinib in myelofibrosis patients with severe thrombocytopenia

13 October 2020 - Completion of submission expected in first quarter 2021. ...

Read more →